SynthesisWorld journal of surgical oncology2025
The role of preoperative sarcopenia in post-nephrectomy prognosis of renal cell carcinoma: an integrated systematic review and meta-analysis.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cancer Cachexia in Advanced Renal Cell Carcinoma: From Molecular Mechanisms to Prognostic Assessment.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAlthough several studies have suggested that sarcopenia is associated with adverse outcomes in kidney cancer patients undergoing nephrectomy, the results have been inconsistent. Therefore, this meta-analysis was conducted to investigate the relationship between sarcopenia and post-nephrectomy survival in kidney cancer patients.
methodsA thorough search was executed across multiple databases, including MEDLINE, Embase, and the Cochrane Library, to identify pertinent studies up to August, 2025. By employing random/fixed effects models, we calculated multivariate-adjusted hazard ratios (HRs) accompanied by their respective 95% confidence intervals (CIs), in strict compliance with the guidelines delineated in the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement.
resultsA total of thirteen studies encompassing 3,142 patients who underwent nephrectomy fulfilled the inclusion criteria. Regarding the thirteen aggregated multivariate estimates, sarcopenia was found to be associated with reduced OS (HR = 1.63, 95% CI: 1.25-2.01) and CSS (HR = 1.93, 95% CI: 1.40-2.45). Nevertheless, our findings suggest that sarcopenia is not correlated with inferior PFS in kidney cancer patients post-nephrectomy (HR = 1.17; 95% CI: 0.92-1.41). The robustness of these findings is substantiated by sensitivity and meta-regression analyses.
conclusionsSarcopenia has been demonstrated to be independently correlated with inferior OS and CSS in individuals who have undergone nephrectomy for kidney carcinoma. These empirical observations highlight the critical necessity of sarcopenia evaluation in the context of risk stratification, patient advisement, and therapeutic strategy formulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.